A Randomized Trial for the Treatment of Refractory Status Epilepticus [PDF]
Background: Refractory status epilepticus (RSE) has a mortality of 16-39%; coma induction is advocated for its management, but no comparative study has been performed. We aimed to assess the effectiveness (RSE control, adverse events) of the first course
Bertschi, Manuel +5 more
core
Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. [PDF]
OBJECTIVE: Benzodiazepines (BZD) are recommended as first-line treatment for status epilepticus (SE), with lorazepam (LZP) and midazolam (MDZ) being the most widely used drugs and part of current treatment guidelines. Clonazepam (CLZ) is also utilized in
Alvarez, V. +6 more
core +1 more source
KCNJ4 variants disrupt inward‐rectifier potassium channel function and cause refractory epilepsy
Abstract Objective Epilepsy is a common neurological disorder with a strong genetic basis, most frequently arising from ion channel dysfunction. Although multiple inwardly rectifying potassium (Kir) channels have been implicated in epileptogenesis, the contribution of KCNJ4, which encodes the Kir2.3 channel, has not previously been established in human
Hu Pan +20 more
wiley +1 more source
Correlation of Malondialdehyde (MDA) and C-reactive Protein (CRP) Level to Neurodevelopmental Outcome in Children After the Episode of Convulsive Type Status Epilepticus [PDF]
Refractory and mortality associated with status epilepticus (SE) were correlated with the degree of inflammation-induced neuronal cell death. This study was aimed to investigate the correlation of oxidative stress (Malondialdehyde, MDA) and inflammation (
Ariani, A. (Ariani) +4 more
core
Variability in pharmacologically-induced coma for treatment of refractory status epilepticus [PDF]
Objective To characterize the amount of EEG suppression achieved in refractory status epilepticus (RSE) patients treated with pharmacologically-induced coma (PIC).
An, J. +5 more
core +1 more source
Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome
Overview of the phase 3 trial evaluating soticlestat as adjunctive therapy in children and young adults with Dravet syndrome. Abstract Objective This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS).
Joseph Sullivan +14 more
wiley +1 more source
Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS [PDF]
Convulsive status epilepticus (CSE) is a major medical emergency associated with a 50 % morbidity rate. CSE guidelines have recommended prompt management for many years, but there is no evidence to date that they have significantly improved practices or ...
Alain Cariou +6 more
core +1 more source
Defining the end point of status epilepticus: A scoping review and framework for standardization
Abstract Status epilepticus (SE) is a life‐threatening neurological emergency with consensus‐driven definitions for onset but no standardized criteria for its end point. This gap creates uncertainty in research and clinical practice. We conducted a scoping review to evaluate how end points have been defined in SE research and to identify key areas of ...
Fawad A. Khan +6 more
wiley +1 more source
Commentary on ‘Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children’, with a response from the review authors [PDF]
Commentary by David McGillivray, Peter Dayan and Martin Pusic The treatment of an acute convulsion can be a lifesaving intervention, especially in cases where the convulsion is likely to be prolonged or leaves the patient susceptible to aspiration or ...
Dayan, Peter +2 more
core +2 more sources
Graphical abstract for the systematic literature review. Abstract Objective Dravet syndrome (DS) places tremendous burden on caregivers owing to the extent of required assistance and impact on daily living, as well as the risk to the individual with DS of premature mortality from sudden unexpected death in epilepsy and morbidity associated with ...
Adam Strzelczyk +8 more
wiley +1 more source

